NZ624446B2 - Methods for treatment of diseases and disorders related to transducin ?-like protein 1 (tbl 1) activity, including myeloproliferative neoplasia and chronic myeloid leukemia - Google Patents
Methods for treatment of diseases and disorders related to transducin ?-like protein 1 (tbl 1) activity, including myeloproliferative neoplasia and chronic myeloid leukemia Download PDFInfo
- Publication number
- NZ624446B2 NZ624446B2 NZ624446A NZ62444612A NZ624446B2 NZ 624446 B2 NZ624446 B2 NZ 624446B2 NZ 624446 A NZ624446 A NZ 624446A NZ 62444612 A NZ62444612 A NZ 62444612A NZ 624446 B2 NZ624446 B2 NZ 624446B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- compound
- cells
- catenin
- beta
- treatment
- Prior art date
Links
- 208000008456 Leukemia, Myelogenous, Chronic, BCR-ABL Positive Diseases 0.000 title claims abstract description 22
- 201000006934 chronic myeloid leukemia Diseases 0.000 title claims abstract description 22
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 10
- 230000002071 myeloproliferative Effects 0.000 title claims abstract description 6
- 230000000694 effects Effects 0.000 title abstract description 43
- 201000010099 disease Diseases 0.000 title abstract description 34
- 102000004169 proteins and genes Human genes 0.000 title abstract description 15
- 108090000623 proteins and genes Proteins 0.000 title abstract description 15
- 102000006612 Transducin Human genes 0.000 title abstract description 14
- 108010087042 Transducin Proteins 0.000 title abstract description 14
- 201000011510 cancer Diseases 0.000 claims abstract description 12
- 150000001875 compounds Chemical class 0.000 claims description 90
- 239000003795 chemical substances by application Substances 0.000 claims description 18
- 150000003839 salts Chemical class 0.000 claims description 13
- 239000011780 sodium chloride Substances 0.000 claims description 13
- 239000003814 drug Substances 0.000 claims description 6
- 102100019516 JAK2 Human genes 0.000 claims description 4
- 101700016050 JAK2 Proteins 0.000 claims description 4
- 102000003964 Histone deacetylases Human genes 0.000 claims description 3
- 108090000353 Histone deacetylases Proteins 0.000 claims description 3
- 102000030951 Phosphotransferases Human genes 0.000 claims 2
- 108091000081 Phosphotransferases Proteins 0.000 claims 2
- 241001243925 Sia Species 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000037361 pathway Effects 0.000 abstract description 16
- -1 anthracene-9,10-dione dioxime compound Chemical class 0.000 abstract description 12
- 102000015735 beta Catenin Human genes 0.000 abstract description 12
- 108060000903 beta Catenin Proteins 0.000 abstract description 12
- 238000003745 diagnosis Methods 0.000 abstract description 5
- 230000002265 prevention Effects 0.000 abstract description 5
- 230000002074 deregulated Effects 0.000 abstract description 3
- 230000003993 interaction Effects 0.000 abstract description 3
- 230000003081 coactivator Effects 0.000 abstract 2
- RZVHIXYEVGDQDX-UHFFFAOYSA-N Anthraquinone Chemical compound C1=CC=C2C(=O)C3=CC=CC=C3C(=O)C2=C1 RZVHIXYEVGDQDX-UHFFFAOYSA-N 0.000 abstract 1
- 210000004027 cells Anatomy 0.000 description 104
- 206010000880 Acute myeloid leukaemia Diseases 0.000 description 57
- 208000007046 Leukemia, Myeloid, Acute Diseases 0.000 description 57
- 239000000203 mixture Substances 0.000 description 16
- 206010059512 Apoptosis Diseases 0.000 description 15
- 230000006907 apoptotic process Effects 0.000 description 15
- 102100016492 CD34 Human genes 0.000 description 13
- 108060001251 CD34 Proteins 0.000 description 13
- 230000004083 survival Effects 0.000 description 9
- UCSJYZPVAKXKNQ-HZYVHMACSA-N 1-[(1S,2R,3R,4S,5R,6R)-3-carbamimidamido-6-{[(2R,3R,4R,5S)-3-{[(2S,3S,4S,5R,6S)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy}-4-formyl-4-hydroxy-5-methyloxolan-2-yl]oxy}-2,4,5-trihydroxycyclohexyl]guanidine Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 8
- 230000001939 inductive effect Effects 0.000 description 7
- 239000002253 acid Substances 0.000 description 6
- 102100015262 MYC Human genes 0.000 description 5
- 108091008108 Myc family Proteins 0.000 description 5
- 230000001640 apoptogenic Effects 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 238000001262 western blot Methods 0.000 description 5
- 102000004121 Annexin A5 Human genes 0.000 description 4
- 108090000672 Annexin A5 Proteins 0.000 description 4
- 210000001185 Bone Marrow Anatomy 0.000 description 4
- 210000000349 Chromosomes Anatomy 0.000 description 4
- 208000002047 Essential Thrombocythemia Diseases 0.000 description 4
- 208000008696 Polycythemia Vera Diseases 0.000 description 4
- 229960005322 Streptomycin Drugs 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- MUBZPKHOEPUJKR-UHFFFAOYSA-N oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 4
- 230000011664 signaling Effects 0.000 description 4
- 210000004369 Blood Anatomy 0.000 description 3
- 102100002974 CDKN1A Human genes 0.000 description 3
- 101710022308 CDKN1A Proteins 0.000 description 3
- 101700033061 GRA5 Proteins 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 239000005536 L01XE08 - Nilotinib Substances 0.000 description 3
- 206010024324 Leukaemias Diseases 0.000 description 3
- 206010028537 Myelofibrosis Diseases 0.000 description 3
- 101700045188 NSG1 Proteins 0.000 description 3
- HHZIURLSWUIHRB-UHFFFAOYSA-N Nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 description 3
- FWZRWHZDXBDTFK-ZHACJKMWSA-N Panobinostat Chemical compound CC1=NC2=CC=C[CH]C2=C1CCNCC1=CC=C(\C=C\C(=O)NO)C=C1 FWZRWHZDXBDTFK-ZHACJKMWSA-N 0.000 description 3
- 229940049954 Penicillin Drugs 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- 208000003476 Primary Myelofibrosis Diseases 0.000 description 3
- 101700020165 RHOA Proteins 0.000 description 3
- 101710037814 TBL1XR1 Proteins 0.000 description 3
- 102100004257 TBL1XR1 Human genes 0.000 description 3
- 101710029715 TCEAL1 Proteins 0.000 description 3
- 101700073473 TPT1 Proteins 0.000 description 3
- 210000003462 Veins Anatomy 0.000 description 3
- 230000001594 aberrant Effects 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 239000012190 activator Substances 0.000 description 3
- 102000004965 antibodies Human genes 0.000 description 3
- 108090001123 antibodies Proteins 0.000 description 3
- 229960000626 benzylpenicillin Drugs 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000004059 degradation Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- XMBWDFGMSWQBCA-UHFFFAOYSA-M iodide Chemical compound [I-] XMBWDFGMSWQBCA-UHFFFAOYSA-M 0.000 description 3
- 230000004807 localization Effects 0.000 description 3
- 230000000051 modifying Effects 0.000 description 3
- 101700045377 mvp1 Proteins 0.000 description 3
- 229960001346 nilotinib Drugs 0.000 description 3
- 102000006255 nuclear receptors Human genes 0.000 description 3
- 101700009395 orf8 Proteins 0.000 description 3
- 229960005184 panobinostat Drugs 0.000 description 3
- 101700012276 wos2 Proteins 0.000 description 3
- 210000002867 Adherens Junctions Anatomy 0.000 description 2
- 210000000601 Blood Cells Anatomy 0.000 description 2
- 102100019529 CCND1 Human genes 0.000 description 2
- 101700080308 CDS4 Proteins 0.000 description 2
- 108060003154 CHLP Proteins 0.000 description 2
- 102000008169 Co-Repressor Proteins Human genes 0.000 description 2
- 108010060434 Co-Repressor Proteins Proteins 0.000 description 2
- 108010058546 Cyclin D1 Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- 108060001084 Luciferase family Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 210000000066 Myeloid Cells Anatomy 0.000 description 2
- 101700070835 NCOR2 Proteins 0.000 description 2
- 102100015085 NCOR2 Human genes 0.000 description 2
- 108009000118 Nuclear Receptors Proteins 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 102000000763 Survivin Human genes 0.000 description 2
- 108010002687 Survivin Proteins 0.000 description 2
- 102100004258 TBL1X Human genes 0.000 description 2
- 101700078954 TBL1X Proteins 0.000 description 2
- 102000006601 Thymidine Kinase Human genes 0.000 description 2
- 108020004440 Thymidine Kinase Proteins 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 150000001412 amines Chemical group 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 210000002798 bone marrow cell Anatomy 0.000 description 2
- 150000001649 bromium compounds Chemical class 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- 238000002487 chromatin immunoprecipitation Methods 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N fumaric acid Chemical compound OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 150000004694 iodide salts Chemical class 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000006011 modification reaction Methods 0.000 description 2
- 201000007224 myeloproliferative neoplasm Diseases 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 229940002612 prodrugs Drugs 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000002829 reduced Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 230000002103 transcriptional Effects 0.000 description 2
- 108091006090 transcriptional activators Proteins 0.000 description 2
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 2
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 2
- 229940121358 tyrosine kinase inhibitors Drugs 0.000 description 2
- PIICEJLVQHRZGT-UHFFFAOYSA-N 1,2-ethanediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- VFWCMGCRMGJXDK-UHFFFAOYSA-N 1-Chlorobutane Chemical class CCCCCl VFWCMGCRMGJXDK-UHFFFAOYSA-N 0.000 description 1
- VUQPJRPDRDVQMN-UHFFFAOYSA-N 1-chlorooctadecane Chemical class CCCCCCCCCCCCCCCCCCCl VUQPJRPDRDVQMN-UHFFFAOYSA-N 0.000 description 1
- WMPPDTMATNBGJN-UHFFFAOYSA-N 2-Phenylethylbromide Chemical class BrCCC1=CC=CC=C1 WMPPDTMATNBGJN-UHFFFAOYSA-N 0.000 description 1
- 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K 2qpq Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-M 3-phenylpropionate Chemical compound [O-]C(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-M 0.000 description 1
- VMAQYKGITHDWKL-UHFFFAOYSA-N 5-methylimidazolidine-2,4-dione Chemical compound CC1NC(=O)NC1=O VMAQYKGITHDWKL-UHFFFAOYSA-N 0.000 description 1
- 101710034857 ATIC Proteins 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 229940009098 Aspartate Drugs 0.000 description 1
- 229940050390 Benzoate Drugs 0.000 description 1
- 210000000481 Breast Anatomy 0.000 description 1
- ZMANZCXQSJIPKH-UHFFFAOYSA-O CC[NH+](CC)CC Chemical compound CC[NH+](CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-O 0.000 description 1
- DSSYKIVIOFKYAU-UHFFFAOYSA-N Camphor Chemical compound C1CC2(C)C(=O)CC1C2(C)C DSSYKIVIOFKYAU-UHFFFAOYSA-N 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 206010007541 Cardiac disease Diseases 0.000 description 1
- 229940001468 Citrate Drugs 0.000 description 1
- 102000016736 Cyclins Human genes 0.000 description 1
- 108050006400 Cyclins Proteins 0.000 description 1
- 210000004292 Cytoskeleton Anatomy 0.000 description 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N DL-aspartic acid Chemical compound OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
- 206010012601 Diabetes mellitus Diseases 0.000 description 1
- 235000017274 Diospyros sandwicensis Nutrition 0.000 description 1
- 230000036826 Excretion Effects 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N Glycerol 3-phosphate Chemical compound OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 241000282838 Lama Species 0.000 description 1
- 210000000265 Leukocytes Anatomy 0.000 description 1
- 210000004185 Liver Anatomy 0.000 description 1
- 210000004072 Lung Anatomy 0.000 description 1
- 230000035779 M Phase Effects 0.000 description 1
- 230000027311 M phase Effects 0.000 description 1
- 101700018321 ML3 Proteins 0.000 description 1
- 206010025650 Malignant melanoma Diseases 0.000 description 1
- 206010028549 Myeloid leukaemia Diseases 0.000 description 1
- 102100011185 NCOR1 Human genes 0.000 description 1
- 101700068087 NCOR1 Proteins 0.000 description 1
- 206010053643 Neurodegenerative disease Diseases 0.000 description 1
- 210000004940 Nucleus Anatomy 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 229950010765 Pivalate Drugs 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N Pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 208000009901 Polycystic Kidney Disease Diseases 0.000 description 1
- 101700025421 RUNX2 Proteins 0.000 description 1
- 102100013037 RUNX2 Human genes 0.000 description 1
- 210000001744 T-Lymphocytes Anatomy 0.000 description 1
- 102100004256 TBL1Y Human genes 0.000 description 1
- 101700004836 TBL1Y Proteins 0.000 description 1
- CBXCPBUEXACCNR-UHFFFAOYSA-N Tetraethylammonium Chemical compound CC[N+](CC)(CC)CC CBXCPBUEXACCNR-UHFFFAOYSA-N 0.000 description 1
- 229940035295 Ting Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 230000001154 acute Effects 0.000 description 1
- 230000002730 additional Effects 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminum Chemical class [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Chemical group N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- YIYZHARUXWKUEN-UHFFFAOYSA-N benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1.NS(=O)(=O)C1=CC=CC=C1 YIYZHARUXWKUEN-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-M benzoate Chemical compound [O-]C(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-M 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-M camphorsulfonate anion Chemical compound C1CC2(CS([O-])(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-M 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-M caproate Chemical compound CCCCCC([O-])=O FUZZWVXGSFPDMH-UHFFFAOYSA-M 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 201000011231 colorectal cancer Diseases 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 150000008050 dialkyl sulfates Chemical class 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-O diethylazanium Chemical compound CC[NH2+]CC HPNMFZURTQLUMO-UHFFFAOYSA-O 0.000 description 1
- SPCNPOWOBZQWJK-UHFFFAOYSA-N dimethoxy-(2-propan-2-ylsulfanylethylsulfanyl)-sulfanylidene-$l^{5}-phosphane Chemical compound COP(=S)(OC)SCCSC(C)C SPCNPOWOBZQWJK-UHFFFAOYSA-N 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- GAFRWLVTHPVQGK-UHFFFAOYSA-N dipentyl sulfate Chemical class CCCCCOS(=O)(=O)OCCCCC GAFRWLVTHPVQGK-UHFFFAOYSA-N 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229940079593 drugs Drugs 0.000 description 1
- 210000002919 epithelial cells Anatomy 0.000 description 1
- 150000002148 esters Chemical group 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N ethanolamine Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000002496 gastric Effects 0.000 description 1
- 230000002068 genetic Effects 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 201000010238 heart disease Diseases 0.000 description 1
- 230000002489 hematologic Effects 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-M heptanoate Chemical compound CCCCCCC([O-])=O MNWFXJYAOYHMED-UHFFFAOYSA-M 0.000 description 1
- 239000003276 histone deacetylase inhibitor Substances 0.000 description 1
- 229940121372 histone deacetylase inhibitors Drugs 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 230000003463 hyperproliferative Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M isothiocyanate Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 230000001527 leukocytic activity Effects 0.000 description 1
- 230000000670 limiting Effects 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 230000003211 malignant Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate Chemical compound CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N nicotinic acid Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 125000004433 nitrogen atoms Chemical group N* 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 230000003000 nontoxic Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 108020004017 nuclear receptors Proteins 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic Effects 0.000 description 1
- 230000004650 oncogenic pathway Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- 239000000546 pharmaceutic aid Substances 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229940075930 picrate Drugs 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
- GLUUGHFHXGJENI-UHFFFAOYSA-N piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 1
- NQRYJNQNLNOLGT-UHFFFAOYSA-N piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 230000002062 proliferating Effects 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000003207 proteasome inhibitor Substances 0.000 description 1
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 1
- 230000001105 regulatory Effects 0.000 description 1
- 230000000754 repressing Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible Effects 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229940086735 succinate Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 230000002195 synergetic Effects 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000001225 therapeutic Effects 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000010798 ubiquitination Methods 0.000 description 1
- ZDPHROOEEOARMN-UHFFFAOYSA-M undecanoate Chemical compound CCCCCCCCCCC([O-])=O ZDPHROOEEOARMN-UHFFFAOYSA-M 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 201000011528 vascular disease Diseases 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
The disclosure discloses utilization of the anthracene-9,10-dione dioxime compound: 2-((3R,5S)-3,5-dimethylpiperdin-1ylsulfonyl)-7-((3S,5R)-3,5-dimethylpiperidin-1-ylsulfonyl)anthracene-9,10-dione dioxime represented by formula (I) for the treatment of cancer, including myeloproliferative neoplasia and chronic myeloid leukemia. Such an anthracene-9,10-dione dioxime compound interrupts the Wnt/beta-catenin pathway and inhibits the deregulated activity of this pathway for the treatment, diagnosis and prevention of beta-catenin pathway-related disorders, as well as disrupting transducin beta-like protein 1 (TBL1) interaction with the coactivator molecule beta-catenin. and chronic myeloid leukemia. Such an anthracene-9,10-dione dioxime compound interrupts the Wnt/beta-catenin pathway and inhibits the deregulated activity of this pathway for the treatment, diagnosis and prevention of beta-catenin pathway-related disorders, as well as disrupting transducin beta-like protein 1 (TBL1) interaction with the coactivator molecule beta-catenin.
Description
Methods for treatment of es and disorders related to transducin B-like
protein 1 (TBL1) activity, including myeloproliferative neoplasia and chronic
myeloid leukemia.
FIELD OF THE INVENTION
The present invention relates to the field of therapeutic methods and uses thereof
to modulate diseases and disorders related to transducin B-like protein 1 (TBL1) activity,
including myeloproliferative neoplasia, chronic myeloid leukemia and acute myeloid
leukemia.
OUND OF THE INVENTION
Cancer is the second leading cause of death in the United States. It presents
complex challenges for the development of new therapies. Cancer is characterized by
the abnormal growth of malignant cells that have undergone a series of genetic
changes that lead to growth of tumor mass and atic properties.
Transducin B-like protein 1 (TBL1) family of proteins has been shown to be
involved in the transcriptional activator by acting as a co-regulator ge factor. The
TBL1 family is composed of TBL1X, TBLlY and TBLR1 proteins. These proteins are
components of the uclear receptor/co-repressor (N-CoR) x where they
act to exchange the co-repressors and co-activators on the complex. SMRT and NCoR
are large co—repressor proteins that are involved in the riptional repression by
many different nuclear receptors. TBL1 family of proteins forms a reversible complex
with NCoR/ SMRT to act as a transcriptional activator for nuclear receptors.
Beta-catenin (B—catenin) is part of a complex of proteins that constitute adherens
junctions (AJs). Ads are necessary for the creation and maintenance of epithelial cell
layers by regulating cell growth and adhesion between cells. B—catenin also anchors the
actin cytoskeleton and may be sible for transmitting the contact tion signal
that causes cells to stop dividing once the epithelial sheet is complete.
Wnt/B-catenin y has been shown to play a role in cancer. Recent studies
have shown that TBL1 is able to bind to B-catenin and recruit the complex to Wnt
responsive promoters to activate specific riptional program. it has also been
shown that TBLt is required for nin to actively transcribe target genes. r,
TBLt appears to protect Bacatenin from ubiquitination (a post-translational modification
by certain enzymes) and degradation. However, the mechanism of the interaction
between TBL‘l and B—catenin is unknown.
Aberrant B—catenin signaling plays a important role in tumorigenesis. ln
particular, colorectal cancer is estimated to have greater than 80% ons in the B-
catenin pathway, g to unregulated oncogenic signaling. Aberrant nin
signaling has been shown to be involved in various cancer types, including melanoma,
breast, lung, liver, gastric, myeloma, and acute myeloid leukemia (AML). Further,
aberrant Wnt/B—catenin signaling has been found in a large number of other disorders,
including osteoporosis, osteoarthritis, polycystic kidney disease, diabetes,
schizophrenia, vascular disease, cardiac disease, hyperproliferative disorders, and
neurodegenerative diseases. roliferative neoplasms (MPNs) are a closely
related group of hematological ancies in which the bone marrow cells that
e the body's blood cells develop and function abnormally. The three main
myeloproliferative neoplasms are Polycythemia Vera (PV), Essential Thrombocythemia
(ET) and Primary Myelofibrosis (PMF). A gene mutation in JAKZ is t in most PV
patients and 50% of ET and PMF patients. The beta catenin pathway is activated in
MPN in many cases and required for survival of these cells.
Chronic Myeloid Leukemia is a form of leukemia characterized by the increased
and unreguiated growth of inantly myeloid cells in the bone marrow and the
accumulation of these cells in the blood that contain the delphia chromosome”,
where a piece of chromosome 9 and a piece of some 22 break off and trade
places to form the bcr—abl fusion gene. CML has activation of several other oncogenic
pathways including the beta catenin pathway which is required for CML cell .
Accordingly, there is a need for agents that are able interrupt the Wnt/B—catenin
pathway and inhibit the deregulated activity of this pathway for the treatment, diagnosis
and prevention of B—catenin pathway—related disorders and diseases.
SUMMARY OF THE INVENTION
The present invention provides methods for treating disease or disorders by
administering a therapeutically effective amount of an agent that inhibits transducin [3—
like protein 1 (TBL1) from binding e-associated molecules. In particular, the
provided methods and compositions relate to the treatment, diagnosis, and/or
prevention of B-catenin ing pathway disorders.
in r preferred embodiment, the B-catenin related disorder es
myeioproliferative neoplasia (MPN), chronic myeloid leukemia (CML) and acute myeloid
leukemia (AML).
in the most preferred embodiment, the provided agent has the following
structure:
iii?
or a pharmaceutically able salt thereof. This agent is referred to as Compound 1
throughout this application.
In a preferred embodiment, TBL‘l is ed from the group consisting of
transducin (beta)—like 1X-iinked (TBLiX), transducin (beta)—like 1Y—linked (TBL‘lY) and
transducin (beta)—iike Ri—linked TBLR1 proteins.
in one embodiment, the activator is atenin.
in another embodiment, the activator is a beta-catenin related protein.
In another embodiment, the ed agent can be used in combination with
other therapeutic agents, ing but not limited to tyrosine kinase inhibitor (including
but not limited to niiotinib), histone deacetyiase inhibitor (including, but not limited to
panobinostat), other anti—cancer agents and other therapeutic agents.
BRIEF DESCRIPTION OF THE DRAWINGS
Figures 1A—1D are bar charts that depict the activity of Compound 1 by itself and
in combination with T610120?) on MPN cells in inducing apoptosis.
Figure 2 is a bar chart that depicts the activity of Compound 1 by itself and in
combination with TG101209 on primary MPN cells ed from patients in inducing
apoptosis.
s 3A and 38 are tables which demonstrate the activity of Compound 1 on
CML cells in inducing apoptosis.
Figures 4A—4C are bar charts that depict the activity of Compound 1 on CML cells
in inducing apoptosis in combination with other agents.
Figure 5A is a series of photographs of CD34+ Primary AML cells, 0034+
Primary FLTS—lTD AML cells; and CD34+ normal AML cells.
Figure 58 is a series of photographs of CD34+ FLT3—lTD Primary AML cells in
control conditions and 16 hours following the administration of Compound 1.
Figure SC is a photograph of the Western blot that depicts the effect of
administration of Compound 1 on AML cells.
Figure 6A is a photograph of the Western blot that demonstrates the effect of
administration of Compound 1 on binding of B-catenin to TBL1 in primary AML cells.
Figure SB is a series of raphs of stained AML cells with and t prior
stration of Compound 1.
Figure 6C is a is a photograph of the Western blot that demonstrates the effect of
administration of Compound 1 on binding of Bacatenin to TBL1 in AML cells.
Figure 7A depicts a bar chart of TOP-FLASH and ASH rase activity
versus ent of AML cells with different amounts of Compound 1
Figure 78 contains the bar chart of the results of chlP (Chromatin
immunoprecipitation) analysis of the effect of treating AML cells with Compound 1.
Figure 70 contains the bar chart of the effect of administering 100 nM of
Compound 1 to AML cells on levels of B-catenin, c—MYC, Cyclin Di and p21 (control).
Figure 8A is a bar chart that shows a % of non-viable cells in CD34+ Primary
FLT3-WT AML cells, CDS4+ Primary FLT3—lTD AML cells and CD34+ Normal cells
treated with various amounts of Compound 1.
Figure 88 is a bar chart that shows a % of able cells in CD34+ CD38—Lin—
y AML cells treated with various amounts of Compound 1.
Figure 8C is a chart that demonstrates the effect of ent with Compound 1
on al of N86 mice engraffed with L3.
Figure 80 is a chef: that demonstrates the effect of treatment with Compound 1
on survival of NSG mice engraffed with Primary FLT3-lTD AML3.
DETAILED DESCRIPTION OF THE lNVENTlON
Definitions
The following tions are used, unless otherwise described.
The term "prodrugs" refers to compounds, including but not limited to monomers
and dimers of the compounds of the invention, which become under physiological
conditions compounds of the invention or the active es of the compounds of the
invention.
The term "active moieties" refers to compounds which are pharmaceutically
active in vivo, whether or not such compounds are compounds of the invention.
The term "subject" includes s, including humans. The terms "patient"
and "subject" are used interchangeably.
The term proliferative Neoplasias” or “MPN” refers to a closely related
group of hematological malignancies in which the bone marrow cells that produce the
body's blood cells develop and function abnormally. The three main myeloproliferative
neoplasms are Polycythemia Vera, Essential Thrombocythemia and Primary
Myeiofibrosis.
The term “Chronic Myeloid Leukemia” or “CML” refers to a cancer of the white
blood cells. it is a form of leukemia characterized by the increased and unregulated
growth of predominantly myeloid cells in the bone marrow and the accumulation of
these cells in the blood that contain the “Phiiadelphia chromosome”, where a piece of
chromosome 9 and a piece of some 22 break off and trade places to form the
bcr—abl fusion gene.
The term "Acute Myeloid Leukemia" or "AML" refers to a cancer of the blood
and bone marrow.
The term "T6101209" refers to a JAK2 inhibitor which is an orally bioavailable,
small molecule, ATP—competitive inhibitor towards several ne s. This
compound is also known as N-tert—butyl[[5—methyl—2~[4-(4—methyipiperazin
yl)anilino] pyrimidin-4—yl]arnino]benzenesulfonamide.
The term "therapeutically effective amount" means the amount of a compound
that, when administered to a subject for treating a disease or disorder, is sufficient to
effect such ent for the disease or disorder. The "therapeutically effective amount"
can vary depending on the variety of factors, including the compound, the er
being treated and the severity of the disorder; activity of the specific compound
employed; the specific composition employed; the age, body weight, general health, sex
and diet of the patient; the time of administration, route of administration, and rate of
excretion of the specific compound employed; the duration of the ent; drugs used
in ation or coincidental with the specific compound employed; and like factors
well known in the medical arts. For example, it is well within the skill of the art to start
doses of the compound at levels lower than required to achieve the desired therapeutic
effect and to gradually increase the dosage until the desired effect is achieved.
In one embodiment, the terms "treating" or ment" refer to ameliorating the
disease or disorder (i.e., arresting or reducing the pment of the disease or at
least one of the clinical symptoms thereof). in another embodiment, "treating" or
"treatment" refers to rating at least one physical parameter, which may not be
nible by the subject. In yet another embodiment, "treating" or "treatment" refers
to modulating the disease or er, either physically, (e.g., stabilization of a
discernible symptom), physiologically, (e.g., stabilization of a physical ter), or
both. In yet another embodiment, "treating" or "treatment" refers to delaying the onset
of the disease or disorder, or even preventing the same.
The phrase "pharmaceutically acceptable salt" means those salts which are,
within the scope of sound medical judgment, le for use in contact with the s
of humans and lower animals without undue toxicity, irritation, ailergic response and the
like and are surate with a reasonable benefit/risk ratio. Pharmaceutically
acceptable salts are well-known in the art. For e, 3. M. Berge et al. describe
pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences 1977, 66: 1 et
seq.
Pharmaceutically acceptable salts include, but are not limited to, acid addition
salts. For example, the nitrogen atoms may form salts with acids. Representative acid
addition salts include, but are not iimited to acetate, adipate, alginate, citrate, aspartate,
benzoate, benzenesulfonate, bisulfate, te, camphorate, camphorsulfonate,
digluconate, glycerophosphate, hemisuifate, heptanoate, hexanoate, fumarate,
hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethansuifonate (isothionate),
lactate, maieate, methanesulfonate, nicotinate, 2-naphthalenesulfonate, oxalate,
oate, pectinate, persulfate, 3—phenylpropionate, picrate, pivalate, propionate,
succinate, te, thiocyanate, phosphate, glutamate, onate, p-toluenesulfonate
and undecanoate. Also, the basic nitrogen-containing groups can be quaternized with
such agents as lower alkyl halides such as , ethyl, propyl, and butyl chlorides,
bromides and iodides; dialkyl sulfates like dimethyl, diethyl, dibutyl and diamyl sulfates;
long chain halides such as decyl, lauryl, myristyl and stearyl chlorides, bromides and
iodides; arylalkyl halides like benzyl and phenethyl bromides and others. Water or oil-
soluble or dispersible ts are thereby obtained. Examples of acids which can be
employed to form ceuticaliy acceptable acid addition salts include such
inorganic acids as hydrochloric acid, romic acid, sulfuric acid and phosphoric
acid and such organic acids as oxalic acid, maleic acid, succinic acid and citric acid.
Pharmaceuticaliy able salts include, but are not limited to, s based
on alkali metals or alkaline earth metals such as lithium, sodium, potassium, calcium,
magnesium and aluminum salts and the like and nontoxic quaternary ammonia and
amine cations including ammonium, ethyiammonium, tetraethylammonium,
methyiammonium, dimethyiammonium, trimethytammonium, triethylammonium,
diethylammonium, and ethyiammonium among others. Other representative organic
amines useful for the ion of base on saits include ethylenediamine,
ethanolamine, diethanoiamine, piperidine, piperazine and the like.
Description of the Invention
The present invention provides methods for treating disease or ers by
administering a therapeutically effective amount of an agent that inhibits transducin i3-
iike protein 1 (TBL1) from binding disease-associated molecules. in particular, the
provided methods and compositions relate to the treatment, diagnosis, and/or
prevention of B—catenin ing pathway disorders in Myeioproiiferative Neoplasia
(MPN), Chronic Myeloid Leukemia (CML), and Acute d Leukemia (AML).
in one aspect, the present invention is directed to a method of treating and/or
ting a B-catenin related disorder comprising administering to a patient in need
thereof a therapeutically effective amount of an agent that binds to the transducin B—like
protein 1 (TBL1) protein thereby preventing binding of B—catenin.
in the most preferred embodiment, the provided agent has the ing
ure:
If”?
or a pharmaceutically acceptabie sait thereof. This compound is referred to as
“Compound 1” throughout the application.
In another preferred embodiment, the B—catenin related disorder es cancer,
including but not limited to MPN, CML, and AML.
in a preferred embodiment, TBL1 is selected from the group consisting of
transducin (beta)-like 1X-linked ), transducin (betaHike 1Y—linked (TBL1Y) and
transducin (beta)—like R1—linked TBLR1 proteins.
nd 1 was originally identified in a cell based screen for its ability to inhibit
the transcriptional activation or B-catenin genes. terization of this nd led
to the discovery that the compound is able to induce the degradation of B-catenin,
interfere with the transcriptional activation complex, and has characteristics of a nuclear
receptor ing pathway modulator. Compound 1 interacts with TBL1 and prevents
B—catenin from ating with TBL1 and leads to beta catenin ation.
This activity of nd 1 was found to inhibit the beta catenin pathway in
cancer cells and cause those cells to undergo apoptosis. Specifically, cell lines derived
from CML patients and cell lines and primary cells derived from MPN patients undergo
apoptosis and growth inhibition in the presence of nd 1. In addition, the activity
of Compound 1 is synergistic with compounds that affect therapeutically important
signaling pathways in these diseases (such as JAK2, BCR—ABL, and HDACs) and can
be used in combination with these agents to ameliorate these diseases in individuals
with the disease.
Thus, in some embodiments, the provided agents can be used in combination
with other therapeutic agents, including but not limited to tyrosine kinase inhibitor
(including but not limited to nilotinib), histone deacetylase inhibitor (including, but not
limited to panobinostat), other anti-cancer agents and other therapeutic agents.
When used in the above or other treatments, a therapeutically effective amount
of one of the compounds of the present invention can be employed in pure form or,
where such forms exist, in pharmaceutically acceptable salt, ester or prodrug form.
Alternatively, the compound can be administered as a pharmaceutical ition
containing the compound of interest in ation with one or more pharmaceutically
acceptable excipients.
The total daily dose of the compounds of this invention administered to a human
or lower animal may range from about 0.0001 to about 1000 mg/kg/day. If desired, the
effective daily dose can be divided into multiple doses for purposes of stration;
consequently, single dose compositions may contain such amounts or submultiples
thereof to make up the daily close.
For a clearer understanding of the invention, details are provided below. These
are merely illustrations and are not to be tood as limiting the scope of the
invention in any way. Indeed, various modifications of the invention in addition to those
shown and described herein will become apparent to those skilled in the art from the
following examples and foregoing description. Such modifications, are also intended to
fall within the scope of the appended claims.
EXAMPLES
Example 1
Activity of Compound 1 on MPN cells in inducing sis.
Briefly, the cell lines HEL 92.1.7 (Figures 1A and 1C) and UKE1 (Figures 18 and
1D) were seeded in medium containing 10% FBS and penicillin/streptomycin. After 24
hours, the cells were treated with either: 1) Compound 1; or 2) Compound 1 in
combination with TG101209 for 48 hours. At the end of treatment, cells were washed
with 1X PBS and d with annexin V and TOPRO3 . The percentages of
tic cells were determined by flow cytometry.
As Figures 1A—1D demonstrate, Compound 1 (referred to as BC2059 in Figures'
legends) was induced apoptosis of both HEL 92.1.7 and UKE1 cells. These apoptosis-
inducement effect was enhanced by TG101209.
Example 2
Activity of nd 1 on y MPN cells ed from patients in inducing
apoptosis and in combination with other agents.
, the CD34+ cells isolated from bone marrow of MPN patients, were
seeded in medium containing 10% FBS and penicillin/streptomycin. After 24 hours, the
cells were d with Compound 1 for 48 hours or Compound 1 in combination with
TG‘lO1209. At the end of treatment, cells were washed with 1X PBS and stained with
annexin V and TOPRO3 iodide. The tages of apoptotic cells were determined by
flow cytometry. Combination index (Cl) was determined using the method of Chou-
Talalay (Adv. Enzyme Regul. 22, 27—55).
Figure 2 is a bar chart that depicts the results of this experiment. As one can see,
Compound 1 (referred to as 802059 in the Figure‘s ) at 100 nM or above induced
apoptosis of CD34+ MPN cells. The addition of TG101209 enhanced this effect.
Example 3
Activity of Compound 1 on CML cells in inducing apoptosis.
Briefly, cell lines K562 (human immortalized myelogenous leukemia line) and
LAMA~84 (a human leucocytic cell line) were seeded in medium containing 10% FBS
and penicillin/streptomycin. After 24 hours, the cells were treated with Compound 1 for
48 hours. At the end of the treatment, the cells were washed with 1X PBS and d
with annexin V and TOPR03 iodide. The percentages of apoptotic cells were
ined by flow cytometry.
Figures 3A and 3B are tables which demonstrate the results of this experiment.
As one can see, treatment with Compound 1 increased the number of apoptotic cells at
GO/G1phase of the cell cycle but did not have significant effect at S or GZ/M phases of
the cell cycle.
Example 4
Activity of Compound 1 on CML cells in ng apoptosis in combination with other
agents.
_11_
Briefly, the cell lines K562 and LAMA-84, were seeded in medium containing
% FBS and llin/streptomycin. After 24 hours, the cells were treated with either:
1) Compound 1 alone; or 2) in combination with panobinostat and nilotinib for 48 hours.
At the end of treatment, cells were washed with 1X PBS and stained with annexin V and
TOPROB iodide. The percentages of apoptotic cells were determined by flow cytometry.
Figures 4A—4C are bar charts that demonstrate the results of this experiment. As
these Figures show, treatment with Compound 1 increased the number of apoptotic
cells in both K562 and LAMA—84 cell lines. nostat and nilotinib enhanced the
s of Compound 1.
Example 5
Activity of Compound 1 in a mouse model of human MPN. We determined the in vivo
anti-MPN activity of Compound 1.
Briefly, ID mice were thally irradiated and HEL 92.1.7 cells were
infused into the tail vein and MPN established. Mice were treated with 15 or 20 mg/Kg
of Compound 1 administered b.i.w for three weeks via the tail vein. Animals were
followed for al after dosing stopped. As compared to the control, Compound 1-
treated mice demonstrated significantly improved survival (p < 001).
Example 6
Effect of Compound 1 on fi—catenin expression and nuclear localization in AML cells.
The purpose of this experiment was to analyze the effect of Compound 1 on B—
catenin expression and nuclear localization in AML cells.
Briefly, CD34+ Primary AML cells, CD34+ y FLT3-lTD AML cells and
CDB4+ Normal cells were stained with anti—B-catenin antibody and DAPl nucleic acid
stain. The raphs of these stains were also . The photographs of the
stained cells are contained in Figure 5A. As these photographs show, there is a lot of
B-catenin expressed in both types of AML cells, and B-catenin is concentrated in nuclei
of these cells.
Figure 58 demonstrates the results of treating CDS4+ Primary FLT3—lTD AML
cells with 100 nM of Compound 1 for 16 hours. As one can see, compared to control
cells (i.e., not treated with Compound 1), this treatment leads to depletion of fi-catenin
expression and nuclear localization in AML cells.
Figure 5C is a photograph of the Western blot that further demonstrates that the
treatment with nd 1 leads to ion of B-catenin expression and nuclear
zation in AML cells. As one can see, the‘AML cells treated with 100 nM of
Compound 1 expressed less of B-catenin, but about the same levels of TBL1, c—MYC,
Survivin and B—actin.
Example 7
Effect of Compound 1 on binding of §~catenin to TBL1 in AML cells.
The purpose of this experiment was to analyze the effect of Compound 1 on
binding of nin to TBL1 in AML cells.
Figure 6A is a photograph of the Western blot that demonstrates that there is
less of B-catenin in primary AML cells after they were treated with 100 nM of
Compound 1 for 8 hours.
Figure 68 is a series of photographs of stained AML cells with and without prior
administration of Compound 1. The top panel depicts control cells (without prior
administration of Compound 1) and the bottom panel depicts AML cells following
administration of 100 nM of Compound 1 for 16 hours. The cells were stained with the
anti-fi-catenin antibody, anti—TBL1 antibody, and DAPl nucleic acid stain. The
photographs of TBL1 and anti-beta-catenin stains were also . As one can see,
administration of Compound 1 depleted the levels of B—catenin and severely disrupted
g of nin to TBL1. Compare especially the top right photograph and the
bottom right photograph.
Figure 6C is a photograph of the n blot that trates that
administration of Compound 1 to AML cells leads to proteasomal degradation of B-
catenin. As one can see, there is less of B-catenin in the AML cells treated with 100 nM
of Compound 1 for 8 hours as compared to non-treated AML cells. However, when 10
nM of zomib (CZ) (a proteasome inhibitor) were administered to the same AML
cells, the amount of B-catenin increased.
Effect of Comgound t on nin at target gene promoters and transcription in AML
cells.
The purpose of this experiment was to analyze the effect of nd 1 on B-
catenin at target gene promoters and transcription in AML cells.
Figure 7A depicts a bar chart of TOP-FLASH and FOP—FLASH luciferase activity
versus treatment of AML cells with ent amounts of Compound 1.
TOP-FLASH is a Transfection grade T—cell factor (TCF) er plasmid
containing two sets (with the second set in the reverse orientation) of three copies of
the TCF binding site (wild type) upstream of the Thymidine Kinase (TK) minimal
promoter and Luciferase open reading frame.
FOP-FLASH is a reporter plasmid containing mutated TCF binding sites is a
negative control.
As Figure 7A demonstrates, the treatment with 20 nM, 50 nM, and 100 nM of
Compound 1 resulted in much lower expression of B—catenin as measured by this
luciferase assay. There was no reduction in FOP~FLASH (negative l). These
results indicate that treatment of AMC cells with Compound 1 results in reduced
expression of B-catenin
Figure 78 contains the bar chart of the results of chlP (Chromatin
immunoprecipitation) analysis of the effect of treating AML cells with Compound 1. As
Figure 7B shows, treatment of AML cells with 200 nM of nd 1 for 8 hours
resulted in reduced amount of promoter DNA of survivin, CCND’l and c-MYC.
Figure 70 contains the bar chart of the effect of administering 100 nM of
Compound 1 to AML cells on levels of B—catenin, c—MYC, Cyclin D1 and p21 (control).
2012/063746
As Figure 7 trates, the treatment with 100 nM of Compound 1 resulted in lower
expression of B—catenin, c-MYC, and Cyclin D1, and much higher expression of p21.
Example 9
Effect of nd 1 on in vitro apoptosis and survival of NSG mice engrafted with
primary AML cells.
The purpose of this experiment was to analyze the effect of Compound 1 on in
vitro apoptosis and survival of N86 mice engrafted with y AML cells.
Figure 8A is a bar chart that shows a % of non—viable cells in 0034+ Primary
FLTS-WT AML cells, CD34+ Primary FLT3-lTD AML cells and CD34+ Normal cells
treated with various amounts of Compound 1. As Figure 8A demonstrates, Compound
1 significantly induced in vitro apoptosis in the both types of AML cells.
Figure 8B is a bar chart that shows a % of non-viable cells in CD34+ CD38—Lin—
Primary AML cells treated with various amounts of Compound 1. As Figure BB
demonstrates, nd 1 significantly induced in vitro apoptosis in the AML cells.
ent with Compound 1 for three weeks, twice per week tail vein infusion,
in NOD—SClD—lLZY receptor deficient (NSG) mice with established AML by OCl-AML3
xenograft cells resulted in ed survival as compared to the control mice. Figure
SC contains a chart that demonstrates the s of this experiment. Both 5 mg/kg
Compound 1 and 10 mg/kg Compound 1 treatments resulted in improved survival, with
the 10 mg/kg dose being more effective.
Very similar results were obtained in NSG mice with primary FLT3—lTD AML
xenograft. As shown in Figure 8D, treatment with 10 mglkg Compound 1 (three weeks,
twice per week intravenous infusion) resulted in a dramatic increase in % survival as
compared to the l mice.
These results strongly suggest that Compound 1 significantly improves survival
of NSG mice engrafted with primary AML cells.
Claims (7)
1. Use of a therapeutically effective amount of a compound having the formula: O O S S N O O N or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating and/or preventing a cancer selected from myeloproliferative neoplasia and or 10 chronic myeloid leukemia.
2. The use of claim 1, wherein said cancer comprises myeloproliferative sia.
3. The use of claim 1, wherein said cancer comprises chronic myeloid leukemia.
4. The use of claim 1, wherein said compound is provided further in combination with an agent that inhibits JAK2 , BCR-ABL kinase, or histone deacetylase.
5. The use of claim 4, wherein said agent inhibits JAK2 kinase.
6. The use of claim 4, n said agent ts BCR-ABL kinase.
7. The use of claim 4, wherein said agent inhibits histone deacetylase.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161556245P | 2011-11-06 | 2011-11-06 | |
US61/556,245 | 2011-11-06 | ||
PCT/US2012/063746 WO2013067547A1 (en) | 2011-11-06 | 2012-11-06 | METHODS FOR TREATMENT OF DISEASES AND DISORDERS RELATED TO TRANSDUCIN β-LIKE PROTEIN 1 (TBL 1) ACTIVITY, INCLUDING MYELOPROLIFERATIVE NEOPLASIA AND CHRONIC MYELOID LEUKEMIA |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ624446A NZ624446A (en) | 2016-01-29 |
NZ624446B2 true NZ624446B2 (en) | 2016-05-03 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10583129B2 (en) | Use of EP4 receptor antagonists for the treatment of NASH-associated liver cancer | |
AU2012332111B2 (en) | Methods for treatment of diseases and disorders related to transducin beta-like protein 1 (TBL 1) activity, including myeloproliferative neoplasia and chronic myeloid leukemia | |
EA038337B1 (en) | Ezh2 inhibitors for treating lymphoma | |
US11147819B2 (en) | EZH2 inhibitors for treating cancer | |
EA028452B1 (en) | Treatment of breast cancer | |
US10464890B2 (en) | PGAM1 inhibitors and methods related thereto | |
US11267809B2 (en) | BAF complex modulating compounds and methods of using the same | |
KR20190018486A (en) | Compounds, compositions and methods for the prophylaxis and / or treatment of cancer | |
US20220323436A1 (en) | Protein kinase c inhibitors for treatment of uveal melanoma | |
CN114025766A (en) | Oxathiazine compounds for inhibiting GAPDH | |
KR20190123270A (en) | Novel spiro and cyclic bis-benzylidine proteasome inhibitors for the treatment of cancer, diabetes and neurological disorders | |
US20190321345A1 (en) | GLUT4 Selective Inhibitors for Cancer Therapy | |
NZ624446B2 (en) | Methods for treatment of diseases and disorders related to transducin ?-like protein 1 (tbl 1) activity, including myeloproliferative neoplasia and chronic myeloid leukemia | |
US20190365680A1 (en) | Use of ep4 receptor antagonists for the treatment of nash-associated liver cancer | |
WO2018232252A1 (en) | Methods to treat gliomas using a stat3 inhibitor | |
US20210338694A1 (en) | Sos1 allosteric site targeting | |
CA3151847A1 (en) | Pharmaceutical composition comprising hdac inhibitor and anti-pd1 antibody or anti pd-l1 antibody | |
JP2020083849A (en) | Pharmaceutical composition for treating or preventing cancer |